Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

South Korea-based developer of RNAi therapeutics developer OliX Pharmaceuticals has announced a global licensing agreement with Eli Lilly.